Diagnovus announced the launch of Engauge-cancer-DLBCL, the first commercial gene expression assay to aid physicians in risk stratification and treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Currently, a patient’s DLBCL risk of disease progression and outcome is assessed by using the International Prognostic Index (IPI). A more accurate classification of patients based on the underlying tumor biology is needed to make more informed treatment decisions. The Engauge-cancer-DLBCL combines a patients’ IPI score and the results of the gene expression assay to add prognostic value beyond an IPI score alone.
The Engauge-cancer-DLBCL kit can be ordered by calling (855) N-GAUGE-U.
For more information call (855) 642-8438 or visit www.diagnovus.com
This article originally appeared on MPR